CSI Market
Sign In | Register

Mirati Therapeutics Inc (MRTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MRTX Annual Cash Flow →
This cash flow overview for Mirati Therapeutics Inc spans from Sep 30 2022 to Sep 30 2023, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-523.40
Depreciation & amortization3.30
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring Costs0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-17.14
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation130.91
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Reversal Of Provision For Lease Resiliation-
License And Up Front Fees-
Fair Value Adjustment Of Share Based Liability-
Investment Income Amortization Of Premium-
Increase Decrease In Right Of Use Assets1.06
Investment Income Net Amortization Of Discount And Premium-16.48
Income taxes0.00
Unrealized Gain (Loss) on Investments-0.09
Increase (Decrease) in Accounts Receivable-13.79
Increase (Decrease) in Accounts Payable and Accrued Liabilities-21.61
Accrued Expense0.00
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Deferred Charges0.00
Other Working Capital-6.77
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.28
Discontinued operations0.00
Net Cash flow from Operating Activities-465.30
Investing Activities
Capital Expenditures-1.03
Sale of Capital Items0.00
Payments to Acquire Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase Decreasein Security Deposits Restricted Cash Equivalents and Marketable Securities-
Increase (Decrease) in Restricted Cash and Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments149.52
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities148.49
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock335.84
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-235.88
Payment Of Reorganization Costs-
Payments Of Warrant Issuance Costs-
Proceeds from Stock Options and Warrant Exercises4.43
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents235.88
Proceeds from Disgorgement of Stockholders Short Swing Profits-
Proceeds From Employee Stock Purchase Plan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities340.27
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-466.32
Total Cash Flow23.46
4 historic quarters locked

Sign in to unlock the full Mirati Therapeutics Inc cash flow history.

Sign In Create Free Account

About Mirati Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-23-036875

Figures are derived from filed reports and may be restated. Historical data is subject to revision.